van der Pijl J W, Daha M R, van den Born J, Verhagen N A, Lemkes H H, Bucala R, Berden J H, Zwinderman A H, Bruijn J A, van Es L A, van der Woude F J
Department of Nephrology, Leiden University Medical Center, The Netherlands.
Diabetologia. 1998 Jul;41(7):791-8. doi: 10.1007/s001250050989.
In diabetic nephropathy, expression of glycosaminoglycan side chains of heparan sulphate proteoglycan in the glomerular basement membrane is reduced proportionally to the degree of proteinuria. We performed a cross-sectional study to evaluate whether non-vascular basement membranes also show a decrease in heparan sulphate side chain staining in patients with diabetic nephropathy. We evaluated the skin basement membrane for extracellular matrix components in the following groups: control subjects (n = 16); patients with Type 1 diabetes and normoalbuminuria (n = 17), microalbuminuria (n = 7), and macroalbuminuria (n = 16); patients with Type 1 diabetes and diabetic nephropathy undergoing renal replacement therapy (n = 13); and non-diabetic patients undergoing renal replacement therapy (n = 21). The following antibodies were used for this immunohistochemical study: monoclonal antibodies against the heparan sulphate side chain (JM403) and core protein (JM72) of the glomerular heparan sulphate proteoglycan; polyclonal antibodies against the core protein (B31); polyclonal antibodies against collagen types I, III, and IV, fibronectin, and laminin; and monoclonal antibodies against the noncollagenous domain of alpha1(collagen IV) and alpha3(collagen IV), against transforming growth factor beta(2G7), and against advanced glycosylation end products (4G9). Expression of heparan sulphate side chains was reduced in the skin basement membrane of patients with overt diabetic nephropathy, of those with Type 1 diabetes undergoing renal replacement therapy, and those with non-diabetic renal failure. Increased intensity of staining was found for collagen type I and advanced glycosylation end products in patients with diabetic nephropathy. Changes in the extracellular matrix of the skin basement membrane seem to be similar to those in the glomerular basement membrane. These findings support the suggestion that patients with diabetic nephropathy also have altered heparan sulphate and collagen staining in extrarenal basement membranes. However, patients with non-diabetic renal failure also had reduced expression of heparan sulphate in the skin basement membrane, suggesting that this finding is not specific for diabetic nephropathy.
在糖尿病肾病中,肾小球基底膜中硫酸乙酰肝素蛋白聚糖的糖胺聚糖侧链表达与蛋白尿程度成比例降低。我们进行了一项横断面研究,以评估非血管基底膜在糖尿病肾病患者中是否也表现出硫酸乙酰肝素侧链染色减少。我们评估了以下几组人群皮肤基底膜中的细胞外基质成分:对照组(n = 16);1型糖尿病且尿白蛋白正常(n = 17)、微量白蛋白尿(n = 7)和大量白蛋白尿(n = 16)的患者;接受肾脏替代治疗的1型糖尿病和糖尿病肾病患者(n = 13);以及接受肾脏替代治疗的非糖尿病患者(n = 21)。本免疫组织化学研究使用了以下抗体:抗肾小球硫酸乙酰肝素蛋白聚糖硫酸乙酰肝素侧链(JM403)和核心蛋白(JM72)的单克隆抗体;抗核心蛋白(B31)的多克隆抗体;抗I型、III型和IV型胶原蛋白、纤连蛋白和层粘连蛋白的多克隆抗体;以及抗α1(IV型胶原蛋白)和α3(IV型胶原蛋白)非胶原结构域、抗转化生长因子β(2G7)和抗晚期糖基化终产物(4G9)的单克隆抗体。显性糖尿病肾病患者、接受肾脏替代治疗的1型糖尿病患者以及非糖尿病肾衰竭患者的皮肤基底膜中硫酸乙酰肝素侧链表达降低。糖尿病肾病患者I型胶原蛋白和晚期糖基化终产物的染色强度增加。皮肤基底膜细胞外基质的变化似乎与肾小球基底膜的变化相似。这些发现支持了糖尿病肾病患者肾外基底膜中硫酸乙酰肝素和胶原蛋白染色也发生改变的观点。然而,非糖尿病肾衰竭患者皮肤基底膜中硫酸乙酰肝素的表达也降低,这表明这一发现并非糖尿病肾病所特有。